Revolutionizing Eye Care: MedevPlus' Portable OCT Device in 2026

30 SEC SUMMARY

MedevPlus, a Bengaluru-based startup, is pioneering portable OCT devices to bring advanced eye care diagnostics to remote areas. Their IXanner 7vn device aims to detect diabetic retinopathy and glaucoma early, addressing the lack of accessible retinal imaging technology in rural India.

TABLE OF CONTENTS

1. Company Overview
2. Products and Innovations
3. Funding and Recognition
4. Market Potential and Future Steps
5. FAQs

Company Overview

Incorporated: 10 June 2018 (Tishyas Medical Device Development Solutions Private Limited)

Founders: Dr Ravi Kiran Manapuram, Sweta Patnaik

Headquarters: Bengaluru

Sector: Medical devices, ophthalmic imaging

Revenue: ₹1.37 crore for the year ended March 2023

Funding Raised: About $323,000 across five seed rounds; latest $128,000 in March 2025

Products: IXanner 7vn portable OCT device; TissueXanner, trademark filed

Paid-up Capital: ₹26.7 lakh

Products and Innovations

Optical coherence tomography (OCT) is a cutting-edge technology used by eye doctors to see beneath the surface of the retina. It functions like an ultrasound but uses light to build a cross-section of the tissue layer by layer. This method is the standard for early detection of diabetic retinal damage and glaucoma.

Traditional OCT machines are large and expensive, typically installed in hospitals. This poses a significant challenge for patients in rural areas who must travel long distances to access these devices.

MedevPlus aims to address this issue with its IXanner 7vn, a portable OCT device designed for comprehensive eye screening outside hospital settings. The company envisions a model where primary-level screening identifies only those cases needing surgery, thereby reducing the burden on specialized medical facilities.

In March 2024, MedevPlus conducted a retinal screening camp in Bengaluru with a local trust, demonstrating the practical application of the IXanner 7vn’s portability.

The company also developed TissueXanner, which uses the same imaging approach for tissue analysis without cutting. The TissueXanner has a trademark filed and is envisioned for applications beyond ophthalmology, including veterinary medicine, biotechnology, agriculture, and industrial manufacturing.

Funding and Recognition

MedevPlus has raised about $323,000 across five seed rounds from seventeen investors, five of whom are institutional. Key investors include VIT-TBI, BIRAC, and BITS Pilani. The most recent funding round was approximately $128,000 in March 2025.

The company has also received support from NIDHI PRAYAS, a Department of Science and Technology scheme for hardware prototypes, and is recognized by Startup India, MSME, AIMED, and DPIIT.

Market Potential and Future Steps

In 2026, MedevPlus showcased its retinal diagnostics at Bharat Innovates in Nice, France, highlighting its commitment to advancing eye care technology. The company’s next challenge is to transition from a working prototype to a product that hospitals and screening programs will purchase in large numbers. This transition hinges on regulatory clearance, pricing strategies, and robust clinical validation.

KEY HIGHLIGHTS

• MedevPlus’ IXanner 7vn aims to bring advanced retinal imaging to remote areas.
• The company has raised $323,000 across five seed rounds.
• MedevPlus is recognized by several government and industry bodies.
• The company demonstrated its retinal screening camp in Bengaluru in March 2024.

FAQs

What is MedevPlus' IXanner 7vn?

The IXanner 7vn is a portable OCT device designed for comprehensive eye screening outside hospital settings, facilitating early detection of diabetic retinopathy and glaucoma.

How does MedevPlus plan to scale its technology?

MedevPlus aims to gain regulatory clearance, optimize pricing, and provide robust clinical validation to make its technology widely adopted by hospitals and screening programs.

What other applications does TissueXanner have?

TissueXanner, another product by MedevPlus, uses the same imaging approach for tissue analysis without cutting and has potential applications in veterinary medicine, biotechnology, agriculture, and industrial manufacturing.

Conclusion

MedevPlus is making significant strides in revolutionizing eye care through its portable OCT devices. With substantial funding, recognition from government bodies, and a clear vision for scaling its technology, the company is well-positioned to address the critical need for accessible retinal imaging in India and beyond.

Call-to-Action

For more information on how MedevPlus is transforming eye care, visit blogy.in.